A natural vitamin A transporter, RBP4, can awaken latent HIV through NF-κB signalling, offering a new angle for cure ...

A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic ...

Human immunodeficiency virus (HIV) infections are still fairly common and an estimated 40 million people worldwide are ...

Knowable Magazine reports on breakthroughs in HIV treatment; engineered antibodies show promise for long-term control, hinting at a functional cure.

Studies have shown that both SARS-CoV-2 and HIV-1 are RNA viruses and have higher mutation rates than DNA viruses. Although both the viruses have been characterized as highly virulent, the manner of ...

The human immunodeficiency virus is classified into two main types: HIV-1 and HIV-2. HIV-1 was discovered first and is more prevalent worldwide, while HIV-2 is less pathogenic and is mostly confined ...

There are two main types of human immunodeficiency virus (HIV) -- HIV-1 and HIV-2. Both can lead to AIDS. However, they're very different from each other. HIV-1 is the most common type. When you hear ...

Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence. In this phase 3, open-label, multicenter, ...

Gilead Sciences, Inc. GILD announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the treatment of HIV met the primary endpoint in the late-stage ARTISTRY-2 study.